Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma

BACKGROUND: We conducted this trial to determine the maximum tolerated dose (MTD) of temsirolimus added to an established regimen comprised of rituximab and cladribine for the initial treatment of mantle cell lymphoma. PATIENTS AND METHODS: A standard phase I cohort of three study design was utilize...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Inwards, D. J., Fishkin, P. A., LaPlant, B. R., Drake, M. T., Kurtin, P. J., Nikcevich, D. A., Wender, D. B., Lair, B. S., Witzig, T. E.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5808677/
https://ncbi.nlm.nih.gov/pubmed/25057177
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu273
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars